An 82% objective response rate in second- and third-line metastatic pancreatic cancer is a number that almost never appears, and Tango Therapeutics reported exactly that on October 23 from its ongoing Phase 1/2 trial of vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitor daraxonrasib. Among 22 efficacy-evaluable patients with MTAP-deleted, RAS-mutant metastatic PDAC, 18 responded, median progression-free survival had not been reached as of the August 20 data cutoff, and the 9-month PFS rate was 88%. All seven initially unconfirmed partial responses were subsequently confirmed after the cutoff date.

The patient population here is narrow but real. MTAP deletion occurs in roughly 28% of PDAC cases, and co-occurrence with RAS mutation narrows that further. Most patients in this cohort (13 of the 22 efficacy-evaluable) were on third-line treatment, a setting where response rates in the single digits are common under standard chemotherapy regimens. The disease control rate was 100%. The safety picture at dose level 1 (200 mg vopimetostat plus 100 mg daraxonrasib daily) was manageable: no dose-limiting toxicities, no withdrawals from treatment-related adverse events, and no Grade 4 or 5 toxicities in 25 safety-evaluable PDAC patients, though Grade 3 events affected 40% of them, mostly stomatitis, rash, and diarrhea. Dose level 2 did not hold up, with three dose-limiting toxicities across two patients, effectively closing that escalation path.

The NSCLC signal adds context. Five patients with MTAP-deleted, RAS-mutant NSCLC at dose level 1 had an 80% ORR with all four responders achieving confirmed partial responses, and no Grade 4 or 5 toxicities. Five patients cannot anchor a conclusion, but the consistency of the response pattern across tumor types reinforces the mechanistic premise: that MTAP deletion creates a selective vulnerability to PRMT5 inhibition, and that pairing a PRMT5 inhibitor with direct RAS suppression compounds that effect. These results were presented at the ESMO 2026 Congress. The trial also includes a vopimetostat-plus-zoldonrasib arm targeting the KRAS G12D mutation specifically, with data not yet fully reported in the filing.

For a disease where the most recent first-line approval arrived only in February 2024 and second-line options remain limited, an 82% ORR with a 9-month PFS rate of 88% in a pretreated population will draw scrutiny. The number to watch next is whether median PFS holds above a clinically meaningful threshold once it is reached, since an unreached median at 7.1 months of median follow-up tells you the curve is steep but not yet where it lands.

Source link: https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613d8k.htm

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.